Aikang Group Announces Strategic Partnerships with Global Healthcare Leaders at CIIE to Advance 'Healthy China 2030'

The 4th China International Import Expo officially opened on November 5, with approximately 350 enterprises from 33 countries and regions participating in the 70,000-square-meter Medical Equipment and Healthcare Products exhibition area, including over 70 Fortune Global 500 companies and industry leaders. This unprecedented scale of participation showcases...China MedicineThe vast growth potential of the healthcare industry.

As a pioneer in China's health management industry, Ikang Group launched public welfare initiatives and established strategic partnerships with multiple Fortune Global 500 healthcare giants, including Danaher, Mammotome, and BD Medical, at the CIIE, to advance the realization of the "Healthy China 2030" strategy.

Launch the "Care for Carnations" Campaign: Caring for Women's Health

On November 6, the launch ceremony of the "Caring for Carnations" Women's Health Initiative, hosted by the China Development Research Foundation and co-organized by Danaher, United Family Healthcare, GE Healthcare, Ikang Health Technology Inc., and other institutions, was officially held at the Danaher booth at the CIIE. Fang Jin, Secretary-General of the China Development Research Foundation (via video); Weng Wenlei, Vice Chairperson of the Shanghai Women's Federation; Li Jin, Co-initiator of the "Caring for Carnations" Women's Health Initiative; Peng Yang, Global Vice President and China Group President of Danaher; Li Bijin, Founder of United Family Healthcare and CEO of New Frontier Health; Liu Ying, General Manager of Non-Public Sector Strategic Partnerships, GE Healthcare China; Wang Zhaohui, Vice President of Ikang Health Technology Inc.; along with other leaders and industry peers, jointly witnessed this significant moment.

With the continuous advancement of social development and urbanization in China, supporting women's physical and mental health, strengthening family development, building harmonious households, and enhancing the well-being of Chinese families in the new era have become the foundational work and a crucial component of high-quality development in contemporary Chinese society. The "Caring for Carnations" Women's Health Initiative aims to respond to the national call, actively implement the *Outline of the "Healthy China 2030" Plan*, mobilize all sectors of society, promote comprehensive care for women's health, raise public health awareness—particularly among women—foster the harmonious development of Chinese families, and improve family well-being.

Zhang Ligang, Founder, Chairman and CEO of Ikang Group, stated: “Ikang Group is committed to health management and improving quality of life as its mission, and caring for women's health is our unshirkable responsibility. Through public welfare initiatives such as the ‘Caring for Carnations’ Women's Health Campaign, the Pink Ribbon Campaign, and the China Women's Cervical Health Promotion Program, we hope to raise awareness of the importance of women's cancer screening. By providing professional screening services and collaborating with our partners, we aim to deliver the most effective treatments to patients. Ikang Group hopes to save more women's lives through ‘early screening, early detection, and early diagnosis,’ helping them achieve a higher quality of life.”

Partnering with Global Industry Leaders to Strategically Expand into the Breast Cancer Market

On the same day, Ikang Group and Mammotome China, a subsidiary of Danaher Corporation, signed a strategic cooperation memorandum of understanding, aiming to safeguard the breast health of Chinese women through more advanced diagnostic and therapeutic methods. The agreement was jointly signed by Qian Zhongjun, General Manager of Mammotome China, and Wang Zhaohui, Vice President of Ikang Group.

iKang Healthcare Group and Mammotome China, a Danaher Company, Sign Strategic Cooperation Memorandum of Understanding

Qian Zhongjun, General Manager of Mammotome China (second from left), Wang Zhaohui, Vice President of Ikang Group (third from left)

Mammotome has long been committed to advancing the legacy of early breast cancer detection technologies and driving innovations in cancer diagnostics to improve patients' quality of life. In 1995, the Mammotome brand developed the vacuum-assisted biopsy system, providing support and education to clinicians worldwide, and became a pioneer in the field of minimally invasive breast biopsy.

Qian Zhongjun, General Manager of Mammotome China, stated: “Mammotome is committed to helping radiologists, ultrasound physicians, and breast surgeons worldwide achieve faster, more convenient, and accurate breast cancer diagnoses. It is crucial for women to undergo further diagnosis and treatment once breast abnormalities are detected during health screenings. Choosing Mammotome’s products to perform minimally invasive vacuum-assisted breast biopsies yields more precise pathological results, providing the optimal window for the prevention and treatment of breast cancer. The deepened strategic partnership between Mammotome and Ikang Group will deliver more comprehensive solutions for breast health concerns among Chinese women.”

As a pioneer in the field of preventive medicine, Ikang Group has long been dedicated to women's breast health. Since 2011, in partnership with 《Fashion Health》, Ikang Group has consecutively hosted the “Pink Ribbon” breast cancer prevention and control campaign for eleven years and published the 《China Women's Health Pink Report》 for ten consecutive years. Through initiatives such as health report publications, public education seminars, and free medical consultations, the campaign aims to raise public awareness of breast health and effectively enhance China's standards for breast cancer prevention, screening, diagnosis, and treatment.

Wang Zhaohui, Vice President of Ikang Group, stated: “Ikang has always been committed to integrating leading industry resources and building a bridge between clients and medical experts. As early as 2017, Ikang launched the ‘iKangCare+ Program (Ikang Care Program)’. For clients found to have breast abnormalities following health examinations at Ikang’s affiliated check-up centers, Ikang provides an expedited medical access channel. This collaboration with Mammotome aims to further advance the early screening, early diagnosis, and early treatment of breast diseases. By leveraging the medical resource advantages of both parties, we will jointly develop an integrated precision medicine solution for the ‘screening, diagnosis, and treatment’ of breast tumors.”

Partnering with Global Industry Leaders to Jointly Safeguard Immunity

Meanwhile, Ikang Group and BD Medical signed a cooperation agreement at the China International Import Expo (CIIE). Leveraging BD Medical’s technological expertise in flow cytometry and Ikang Group’s experience in health management, both parties will jointly advance the popularization and application of immunity assessment in the health management sector. Hu Yiqing, Vice President of Biosciences for BD Greater China, and Wang Zhaohui, Vice President of Ikang Group, among others, attended and witnessed the signing ceremony.

Ikang Group and BD Medical Sign Cooperation Agreement

Hu Yiqing, Vice President, BD Biosciences Greater China (second from left), Wang Zhaohui, Vice President, Ikang Group (third from left)

Through this collaboration, both parties will leverage their respective strengths to integrate flow cytometry technology into health management, enabling the quantification of previously intangible immune functions. This will further explore the value of immune assessment in early disease warning and sub-health risk alerting, while investigating targeted strategies to balance immune status and ensure the optimal functioning of the body’s natural defense mechanisms.

Wang Zhaohui, Vice President of Ikang Group, stated: "Cellular immunity assessment is an integral component of the 'early screening, early assessment, and early intervention' Three-Early health management model. It provides a quantitative evaluation of cellular immune levels for individuals in sub-optimal health or those with chronic conditions, offering an objective reference for assessing the effectiveness of health management interventions. We look forward to deepening our collaboration through this partnership to facilitate the widespread adoption of the cellular immunity assessment program, enabling a broader public to benefit from it."

Hu Yiqing, Vice President of Biosciences for Greater China at BD, stated: “We are delighted to partner with Ikang Group to extend BD’s established products from the disease sector into the field of health management. Leveraging advanced technologies and global expertise, BD Biosciences will drive the implementation of flow cytometry-based immune assessment technology in health screening centers, thereby developing health management solutions based on precise, dynamic, and personalized immunity assessments. This will further elevate public health management standards and support the ‘Healthy China 2030’ strategy.”

In recent years, Ikang has been committed to technological innovation and service upgrades. By introducing advanced technologies such as artificial intelligence and genetic testing, and proactively developing early cancer screening initiatives, Ikang has partnered with enterprises including New Horizon Health, Genetron Health, Airdoc, Benchmark Diagnostics, and Hanwei Intelligence to integrate numerous advanced testing programs into its network of health examination centers. Ikang’s participation in the China International Import Expo (CIIE), where it will engage with world-class international medical enterprises to discuss the future prospects of healthcare and collaborate to advance the grand vision of a "Healthy China", reflects the strategic direction Ikang has consistently pursued.

About Mammotome China

Mammotome China is an independently operated subsidiary of Danaher, a renowned U.S. Fortune 500 company. As a global innovator in science and technology, Danaher is dedicated to helping customers worldwide tackle complex challenges and improve quality of life. With a portfolio of numerous world-renowned brands and operations spanning every continent, Danaher is a leading global life sciences and in vitro diagnostics company. Danaher’s portfolio features Mammotome, a renowned brand in the field of minimally invasive breast biopsy. The Mammotome brand is committed to advancing early breast cancer biopsy and diagnostic technologies to improve patients' quality of life. In 1995, Mammotome developed the vacuum-assisted biopsy system, providing support and education to clinicians worldwide, and established itself as a pioneer in minimally invasive breast biopsy. Headquartered in the United States, Mammotome products are sold in over 50 countries globally.

About BD

BD is a global medical technology company advancing the world of health by improving medical discovery, enhancing diagnostic outcomes, and elevating the quality of care. BD focuses on and supports every frontline healthcare professional, dedicated to developing innovative technologies, services, and solutions that improve clinical outcomes for patients and optimize clinical workflows for healthcare providers. Together with its 70,000 associates worldwide, BD is driven by a shared passion and commitment to improving patient outcomes, providing clinical staff with safe and efficient medication administration workflows, empowering laboratory scientists to diagnose diseases more effectively, and enabling researchers to develop next-generation diagnostics and therapeutics. With a presence in nearly every country, BD actively collaborates with organizations worldwide to jointly address the most pressing global health challenges. Through close collaboration with customers, BD is committed to improving treatment outcomes, reducing healthcare costs, and enhancing diagnostic efficiency, thereby strengthening safety for both patients and healthcare workers and expanding access to care.

About Ikang Group

Ikang Group is China's leading mid-to-high-end chain health examination and health management group. Through its multiple brands, it provides corporate clients, families, and individuals with high-quality health management and medical services, including health checkups, disease screening, dental care, private physician services, occupational healthcare, vaccinations, and anti-aging treatments. As of early November 2021, Ikang Group (including its M&A funds) operates 155 health examination and medical centers in 59 major cities across China. Additionally, it has established a cooperative network with over 800 medical institutions in more than 200 cities across China.